Skip to content

Wise Practice of Chinese Hemodialysis (WISHES)

Wise Practice of Chinese Hemodialysis (WISHES)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03001921
Enrollment
30000
Registered
2016-12-23
Start date
2013-12-01
Completion date
2029-12-01
Last updated
2026-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haemolyses and Related Conditions

Keywords

Hemodialysis, Patient survival, Quality of life, Hemodialysis access

Brief summary

The investigators are registering all HD patients at recruited hospitals and developing a HD database in China. Patients will be follow-up every 3 months, and both baseline and follow-up information will be entered into the registration system. The patient survival, technical survival, patency rate of access, quality of life and residual renal function for HD patients will be compared using the HD database.

Detailed description

The investigators are registering all end stage renal disease (ESRD) patients receiving hemodialysis (HD) treatment, and developing a HD database in China. Patients' demographic characteristics (including age, gender, height, weight, BMI, smoking, drinking, and education), clinical characteristics (including systolic blood pressure, diastolic blood pressure, primary cause of ESRD, and lab measurements of serum, urine, and access patency), complications, drug information and scores of quality of life at the baseline will be collected. Patients will be follow-up every 3 month, the demographic and clinical characteristics, complications and drug information of patients will be collected at each visit. The investigators also record the outcome at each visit, such as mortality (including all-cause mortality and cardiovascular disease mortality), technical survival, kidney transplantation, transfer to peritoneal dialysis, hospitalization, access failure,etc. The patient survival, technical survival, patency rate of access, quality of life and residual renal function for HD patients will be compared using the HD database.

Interventions

OTHERNo intervention

Registration of all HD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospital which have signed the contract in China.

Sponsors

Sun Yat-sen University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

End stage renal disease patients receiving hemodialysis treatment.

Exclusion criteria

No

Design outcomes

Primary

MeasureTime frame
Patient survival of HD patients10 years

Secondary

MeasureTime frame
Quality of life evaluated using SF36 scale for HD patients10 years
Patency rate of access for HD patients10 years

Countries

China

Contacts

CONTACTXueqing Yu, M.D. & Ph.D.
yuxq@mail.sysu.edu.cn
CONTACTXunhua Zheng, M.D. & Ph.D.
wilson_zxh@126.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 16, 2026